A Practical Walkthrough for Biologics Sponsors

For years, sponsors developing biologic therapeutics navigated a patchwork of regional expectations for bioanalytical method validation. A study designed to satisfy FDA bioanalytical method validation (BMV) guidance did not always map cleanly onto EMA expectations, and submissions intended for multiple regions often required duplicated or reconciled validation work. The adoption of ICH M10 changed that landscape by harmonizing the core scientific and documentation requirements for bioanalytical assays across major regulatory regions. For sponsors advancing biologics through global programs, understanding what M10 actually asks for—and where it leaves room for scientific judgment—is now a practical necessity rather than a regulatory footnote.

This walkthrough breaks down the validation parameters that matter most under ICH M10, with particular attention to the considerations that arise when the analyte is a biologic rather than a small molecule.

What is ICH M10 and why does it matter?

ICH M10 is the harmonized guideline on bioanalytical method validation developed under the International Council for Harmonisation. It establishes a common framework for validating the assays used to measure drug concentrations in biological matrices supporting pharmacokinetic and toxicokinetic evaluations. Because it was adopted across ICH regions, a single validation package built to M10 expectations is broadly acceptable to FDA, EMA, and other participating authorities, reducing the friction that previously came from reconciling FDA BMV guidance with EMA requirements.

For biologics sponsors specifically, M10 matters because it formalizes expectations for ligand-binding assays alongside chromatographic methods, recognizing that the analytical challenges of measuring a large, structurally complex molecule differ meaningfully from those of a small molecule. The guideline does not eliminate scientific judgment, but it does set a consistent baseline for what a defensible validation looks like.

Notably, the M10 is specific that ligand binding assays and chromatographic methods are in scope and that the bioanalysis of biomarkers and immunogenicity are not within the scope of the guideline.

Which validation parameters does ICH M10 require?

M10 organizes a full validation around a defined set of performance characteristics. Each is intended to demonstrate that the method produces reliable, reproducible results across the conditions the assay will encounter in study sample analysis. The core parameters include:

• Calibration curve and range—establishing the relationship between concentration and response, with acceptance criteria for the back-calculated standards across the validated range
• Accuracy and precision—assessed within and between runs at multiple concentration levels spanning the curve, including at the lower limit of quantification
• Selectivity and specificity—confirming the method measures the intended analyte without interference from matrix components or related substances
• Matrix effect—particularly relevant for biologic matrices, where endogenous components can suppress or enhance signal
• Carryover—verifying that signal from a high-concentration sample does not contaminate a subsequent low-concentration sample
• Dilution linearity and integrity—demonstrating that samples above the upper limit can be diluted into range without bias
• Stability—covering the analyte across the storage, handling, and processing conditions samples will actually experience

The expectation is not simply that each box is checked, but that the validation is designed around how the assay will be used. A method validated over a range that does not bracket anticipated study concentrations, for example, invites questions regardless of how cleanly the individual parameters pass.

How does ICH M10 treat incurred sample reanalysis?

Incurred sample reanalysis (ISR) is one of the areas where M10 codifies an expectation that sponsors sometimes underestimate. ISR involves reanalyzing a subset of study samples to confirm that the original reported concentrations are reproducible in actual incurred samples—not just in the spiked quality controls used during validation. The rationale is that incurred samples can contain metabolites, binding proteins, or other components not present in validation controls, and these can affect reproducibility in ways the initial validation might not surface.

Under M10, ISR is generally expected for studies supporting regulatory submissions, with predefined acceptance criteria and a defined proportion of samples selected for reanalysis. Treating ISR as an afterthought is a common pitfall; building the sampling plan and acceptance criteria into the study design from the outset avoids scrambling to reconstruct a defensible approach late in a program.

How do M10 expectations differ for ligand-binding assays?

This is where the depth of assay-specific experience matters most. Ligand-binding assays—the workhorse format for measuring many biologic therapeutics and their associated antibodies—behave differently from chromatographic methods, and M10 acknowledges this with format-specific considerations rather than forcing a single template onto every method.

Calibration curves for ligand-binding assays are typically nonlinear and modeled with a four- or five-parameter logistic fit, which changes how curve fitting and anchor points are handled compared with a linear chromatographic standard curve. Selectivity assessment carries additional weight because matrix components and related endogenous molecules can interfere with binding. Minimum required dilution, parallelism, and the behavior of the assay near the limits of quantification all demand attention that a small-molecule-centric reading of the guideline would miss. Sponsors are well served by a partner whose familiarity with these assays runs deep enough to anticipate where a ligand-binding method will be challenged, rather than discovering it during sample analysis.

What documentation survives a regulatory inspection?

A validation is only as strong as the record that supports it. M10 reinforces that the validation report, the underlying raw data, and the standard operating procedures must tell a coherent and complete story. Documentation that survives inspection generally shares a few characteristics: it predefines acceptance criteria before runs are executed, it captures deviations and their dispositions transparently rather than quietly excluding inconvenient data, and it traces every reported result back to source records without gaps.

Inspectors are not only confirming that the numbers passed; they are evaluating whether the process that produced those numbers was controlled and reproducible. A clean validation report paired with disorganized or inconsistent raw data raises more concern than it resolves. Sponsors should expect their bioanalytical work to be defensible not just at the level of the summary table, but all the way down to the instrument records and analyst notes.

Conclusion

ICH M10 gives biologics sponsors a harmonized foundation, but it rewards methods that are designed with the end use, the matrix, and the assay format in mind. The parameters are well defined; the judgment lies in applying them to the specific analyte and study context. For sponsors developing biologics, working with a bioanalytical partner who understands both the regulatory framework and the practical behavior of the relevant assays is the most reliable way to produce validation packages that hold up across regions and across inspections.